Astellas Pharma Inc.
ALPMF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $19,881,791 | $2,484,090,086 | $2,658,082,002 | $2,776,090,150 |
| - Cash | $1,940,485 | $215,399,000 | $188,372,000 | $179,865,000 |
| + Debt | $5,006,044 | $889,490,000 | $831,426,000 | $915,364,000 |
| Enterprise Value | $22,947,350 | $3,158,181,086 | $3,301,136,002 | $3,511,589,150 |
| Revenue | $3,544,403 | $505,794,000 | $459,294,000 | $517,408,000 |
| % Growth | -99.3% | 10.1% | -11.2% | – |
| Gross Profit | $2,609,820 | $410,965,000 | $382,436,000 | $418,885,000 |
| % Margin | 73.6% | 81.3% | 83.3% | 81% |
| EBITDA | $1,042,162 | $151,845,000 | $101,785,000 | $126,058,000 |
| % Margin | 29.4% | 30% | 22.2% | 24.4% |
| Net Income | $535,480 | $68,422,000 | $74,896,000 | -$97,660,000 |
| % Margin | 15.1% | 13.5% | 16.3% | -18.9% |
| EPS Diluted | 0.3 | 38.11 | 41.19 | -54.57 |
| % Growth | -99.2% | -7.5% | 175.5% | – |
| Operating Cash Flow | $1,551,359 | $54,837,000 | $101,075,000 | $16,026,000 |
| Capital Expenditures | -$90,827 | -$12,808,000 | -$9,699,000 | $2,294,000 |
| Free Cash Flow | $1,460,532 | $42,029,000 | $91,376,000 | $18,320,000 |